The size of the Autoimmune Diagnostics Market in Europe was worth USD 3.64 billion in 2019 and estimated to reach USD 4.38 billion by the end of 2024 with a growing potential of 3.76%.
Autoimmune diseases arise once the immune system attacks one or more of the body's normal parts as if they were invaders. When the immune system fails to identify "self" it may produce immune cells or antibodies that target its own tissues, cells, and organs. Developed countries of Europe have a projected high occurrence rate of autoimmune disorders compared to other regions of the autoimmune disease diagnostics. The strike rate of autoimmune diseases is more in women compared to men. The presence of large untapped opportunities available in the developing Eastern European countries is expected to fuel the growth of the market.
High occurrence of autoimmune disorders, Supportive government policies, increasing public awareness, increased government funding aimed at improving healthcare infrastructure, the introduction of advanced technologies such as novel biomarkers and portable diagnostic equipment are the major factors driving the growth of the market.
The key restraints that inhibiting the growth of the autoimmune diagnostics market are the low prevalence of localized autoimmune disorders as compared to systemic diseases and the growing rate of diagnostics errors.
This report is segmented & sub-segmented into the following categories:
Companies leading the European Autoimmune disease market profiled in this report are Bio-Rad, Siemens Healthcare, Abbott Laboratories, Crescendo Bioscience, Roche Diagnostics SQI Diagnostics, AESKU Diagnostics, INOVA Diagnostics Inc., BioMerieux SA, Beckman Coulter Inc., Hemagen Diagnostics, Quest Diagnostics, Eli Lilly and GlaxoSmithKline Plc.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Test Type
5.1.1 Autoantibody Tests
5.1.2 Antinuclear Antibody Tests
5.1.3 Complete Blood Count (CBC)
5.1.4 C - reactive protein (CRP)
5.1.5 Comprehensive Metabolic panel
5.1.6 Urinalysis
5.1.7 Erythrocyte Sedimentation Rate (ESR)
5.1.8 Others
5.2 By Disease Type
5.2.1 Localized auto immune disease diagnostics
5.2.1.1 Graves' Disease
5.2.1.2 Hashimoto's Thyroiditis
5.2.1.3 Multiple Sclerosis
5.2.1.4 Type 1 diabetes
5.2.1.5 Psoriasis
5.2.1.6 Others
5.2.2 Systemic auto immune disease diagnostics
5.2.2.1 Rheumatoid Arthritis (RA)
5.2.2.2 Ankylosing Spondylitis
5.2.2.3 Systemic Lupus Erythematosus (SLE)
5.3 By End Users
5.3.1 Hospitals
"5.3.2 Research centers
"
5.3.3 Diagnostic laboratories
6. Geographical Analysis
6.1 Introduction
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Bio-Rad
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Siemens Healthcare
8.3 Abbott Laboratories
8.4 Crescendo Bioscience
8.5 Roche Diagnostics
8.6 SQI Diagnostics
8.7 AESKU Diagnostics
8.8 INOVA Diagnostics
8.9 BioMerieux SA
8.10 Beckman Coulter Inc.
8.11 Hemagen Diagnostics
8.12 Quest Diagnostics
8.13 Eli lilly
8.14 Glaxosmithkline Plc
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
